| miRNA-7 and miRNA-324-5p regulate alpha9-Integrin expression and exert anti-oncogenic effects in rhabdomyosarcoma C Molist, N Navarro, I Giralt, P Zarzosa, G Gallo-Oller, G Pons, ... Cancer Letters 477, 49-59, 2020 | 30 | 2020 |
| Dickkopf proteins and their role in cancer: a family of Wnt antagonists with a dual role I Giralt, G Gallo-Oller, N Navarro, P Zarzosa, G Pons, A Magdaleno, ... Pharmaceuticals 14 (8), 810, 2021 | 21 | 2021 |
| Integrin alpha9 emerges as a key therapeutic target to reduce metastasis in rhabdomyosarcoma and neuroblastoma N Navarro, C Molist, J Sansa-Girona, P Zarzosa, G Gallo-Oller, G Pons, ... Cellular and Molecular Life Sciences 79 (11), 546, 2022 | 9 | 2022 |
| Dickkopf-1 inhibition reactivates Wnt/β-catenin signaling in rhabdomyosarcoma, induces myogenic markers in vitro and impairs tumor cell survival in vivo I Giralt, G Gallo-Oller, N Navarro, P Zarzosa, G Pons, A Magdaleno, ... International Journal of Molecular Sciences 22 (23), 12921, 2021 | 9 | 2021 |
| A mechanism-based sphingosine-1-phosphate lyase inhibitor G Pons, D Riba, M Casasampere, E Izquierdo, JL Abad, G Fabriàs, ... The Journal of Organic Chemistry 85 (2), 419-429, 2019 | 7 | 2019 |
| Targeting the hedgehog pathway in rhabdomyosarcoma P Zarzosa, L Garcia-Gilabert, R Hladun, G Guillén, G Gallo-Oller, G Pons, ... Cancers 15 (3), 727, 2023 | 6 | 2023 |
| TRIB3 silencing promotes the downregulation of Akt pathway and PAX3-FOXO1 in high-risk rhabdomyosarcoma G Gallo-Oller, G Pons, J Sansa-Girona, N Navarro, P Zarzosa, ... Experimental Hematology & Oncology 13 (1), 38, 2024 | 3 | 2024 |
| Analysis of cancer genomic amplifications identifies druggable collateral dependencies within the amplicon G Pons, G Gallo-Oller, N Navarro, P Zarzosa, J Sansa-Girona, ... Cancers 15 (6), 1636, 2023 | 2 | 2023 |
| Combined inhibition of MDM2 and PARP lead to a synergistic anti-tumoral response in p53 wild-type rhabdomyosarcoma G Pons, G Gallo-Oller, L García-Gilabert, P Zarzosa, J Sansa-Girona, ... Cancer Research 84 (6_Supplement), 5473-5473, 2024 | 1 | 2024 |
| Combined inhibition of MDM2 and PARP lead to a synergistic anti-tumoral response in p53 wild-type rhabdomyosarcoma models G Pons, P Zarzosa, G Gallo-Oller, A Wenz, M Lapins, L Garcia-Gilabert, ... bioRxiv, 2024.12. 03.626050, 2024 | | 2024 |
| THE ONCOGENIC ROLE OF HEDGEHOG PATHWAY CO-RECEPTORS IN RHABDOMYOSARCOMA: EXPANDING KNOWLEDGE TO DISCOVER NEW THERAPEUTIC TARGETS J Roma, P Zarzosa, S Gallego Melcon, J Sanchez De Toledo, L Moreno, ... PEDIATRIC BLOOD & CANCER 69, S258-S259, 2022 | | 2022 |
| A novel and potent strategy for blocking the Hedgehog pathway to treat rhabdomyosarcoma P Zarzosa, N Navarro, J Sansa-Girona, G Pons, G Gallo-Oller, ... European Journal of Cancer 174, S28, 2022 | | 2022 |
Gabriel Gallo-OllerDISIT BiotechVerified email at disitbiotech.com
